📰 Study Comparing Risankizumab News
Study Comparing Risankizumab News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Study Comparing Risankizumab. Real-time updates on events, politics, business and more.
November 23, 2022
- Third approved indication for SKYRIZI® (risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohns disease in the European Union (EU)...
September 19, 2022
- CHMP positive opinion is based on results from three Phase 3 studies: two for induction and one for maintenance1,2 - Crohns disease is a chronic, systemic...
September 10, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in...
February 28, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI®...
February 1, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present further analyses on HUMIRA® (adalimumab) and the investigational uses of risankizumab (SKYRIZI®) and...
November 30, 2021
/PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab...
November 30, 2021
/PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab...
November 30, 2021
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA) - read this article along with other careers information, tips and advice on BioSpace
November 5, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating...
November 5, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2, evaluating...